In-vitro activity of quinupristin/dalfopristin, levofloxacin and moxifloxacin against fusidic acid and rifampicin-resistant strains of methicillin-resistant Staphylcoccus aureus (MRSA) from Malaysian hospitals

Medical Journal of Malaysia

Volumn 60, Issue 4, 2005, Pages 411-415

  Norazah, Ahmad ^a   Lim, V K E ^b   Rohani, M Y ^a   Kamel, A G M ^b,c  

^a INSTITUTE FOR MEDICAL RESEARCH   (Malaysia)

^b INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

^c UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

Author keywords

Levofloxacin; Moxifloxacin MIC MRSA; Quinupristin dalfopristin

Indexed keywords

ANTIBIOTIC AGENT; DALFOPRISTIN PLUS QUINUPRISTIN; FUSIDIC ACID; LEVOFLOXACIN; MOXIFLOXACIN; RIFAMPICIN; ANTIINFECTIVE AGENT; DALFOPRISTIN; DRUG DERIVATIVE; HETEROCYCLIC COMPOUND; OFLOXACIN; QUINOLINE DERIVATIVE; QUINUPRISTIN; VIRGINIAMYCIN;

ALTERNATIVE MEDICINE; ARTICLE; DRUG ACTIVITY; DRUG SENSITIVITY; IN VITRO STUDY; MALAYSIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PUBLIC HOSPITAL; DISEASE PREDISPOSITION; DRUG EFFECT; HUMAN; MICROBIOLOGICAL EXAMINATION; MULTIDRUG RESISTANCE; PENICILLIN RESISTANCE; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; DISEASE SUSCEPTIBILITY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FUSIDIC ACID; HUMANS; MALAYSIA; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; QUINOLINES; RIFAMPIN; STAPHYLOCOCCUS AUREUS; VIRGINIAMYCIN;

EID: 33646675107     PISSN: 03005283     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Guidelines on the use of Antibiotics. Ministry of Health, Malaysia. 1994.
2. Rohani MY, Zainuldin MT, Koay AS, Lau MG. Antibiotic Resistance Patterns of Bacteria Isolated in Malaysian Hospitals. Int Med J 1999; 6: 47-51.
3. Pechere JC. Streptogramins: a unique class of antibiotics. Drugs 1996; 51 Suppl.:13-19.
4. Archer G, Auger P, Doern G et al. RP 59500, a new streptogramin highly active against recent isolates of North American staphylococci. Diag Microb Inf Dis 1993; 16: 223-26.
5. Andrews JM, Wise R. The in-vitro activity of a new semi-synthetic streptogramin compound RP 59500, against staphylococci and respiratory pathogens. J Antimicrob Chemother 1994; 33; 849-53.
6. Prado V, Giangrieco M, Duran C et al. In-vitro comparative activity of moxifloxacin and other antimicrobials against respiratory pathogens. Rev Med Chil 2000; 128: 1319-26.
7. Fujiue Y, Kuwabara M, Muroki K et al. Results of antimicrobial susceptibilities of strains clinically isolated at 8 institutions in Hiroshima City to major oral antimicrobial drugs, mainly new quinolone drugs. Hiroshima Levofloxacin Susceptibility Surveillance Group. Jpn J Antibiot 2000; 53: 409-21.
8. National Committee for Clinical Laboratory Standards (NCCLS) guidelines National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests, 7th edn. Villanova, PA, NCCLS. Approved standard: M2-A7. 2000.
9. Toma E. Barriault D. Antimicrobial activity of fusidic acid and disk diffusion susceptibility testing criteria for gram-positive cocci. J Clin Microbiol 1995; 33: 1712-15.
10. Barry AL, Fuchs PC, Brown SD. Provisional interpretive criteria for quinupristin/dalfopristin susceptibility tests. J Antimicrob Chemother. 1997; 39 Suppl A: 87-92.
11. Barry A, Fuchs P, Tenover F et al. Interpretive criteria and quality control for antimicrobial susceptibility tests of levofloxacin. Eur J Clin Microbiol Infect Dis. 1994; 13: 822-6.
12. Abb J. In vitro activity of linezolid, quinupristin-dalfopristin, vancomycin, teicoplanin, moxifloxacin and mupirocin against methicillin- resistant Staphylococcus aureus: comparative evaluation by the E test and a broth microdilution method. Diagn Microbiol Infect Dis. 2002; 43: 319-21.
13. Morrissey I, Farrell DJ, Bakker S et al. Molecular characterization and antimicrobial susceptibility of fluoroquinolone-resistant or -susceptible Streptococcus pneumoniae from Hong Kong. Antimicrob Agents Chemother 2003; 47: 1433-5.
14. Eliopoulos GM. Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin Infect Dis 2003: 36: 473-81.
15. Nikolaidis P, Metallidis S, Katikaridou E et al. Comparative in vitro activity of quinupristin/dalfopristin and seven other antimicrobials against methicillin-susceptible and methicillin-resistant nosocomial Staphylococcus aureus bloodstream isolates. J Chemother 2002; 14: 544-6.
16. Gales AC, Sader HS, Jones RN. Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia in Latin America: frequency of occurrence and antimicrobial susceptibility profile: results from the SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn Microbiol Infect Dis 2002; 44: 301-11.
17. Vouillamoz J, Entenza J.M, Feger C et al. Quinupristin-dalfopristin combined with beta-lactams for treatment of experimental endocarditis due to Staphylococcus aureus constitutively resistant to macrolide-lincosamide- streptogramin B antibiotics. Antimicrob Agents Chemother 2000; 44: 1789-95.
18. Drew RH, Perfect JR, Srinath L et al. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group. J Antimicrob Chemother 2000; 46: 775-84.
19. Luh KT, Hsueh PR, Teng LJ et al. Quinupristin-dalfopristin resistance among Gram-positive bacteria in Taiwan. Antimicrob Agent Chemother 2000; 44: 3374-80.
20. Siegrist HH, Nepa MC, Jacquet A. Susceptibility to levofloxacin of clinical isolates of bacteria from intensive care and haematology/oncology patients in Switzerland: a multicentre study. J Antimicrob Chemother 1999; 43 Suppl C: 51-4.
21. Entenza JM, Vouillamoz J, Glauser MP et al. Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus. Antimicrob Agents Chemother 1997; 41: 1662-7.
22. Malathum K, Singh KV, Murray BE. In vitro activity of moxifloxacin, a new 8-methoxyquinolone, against gram-positive bacteria. Diagn Microbiol Infect Dis 1999; 35: 127-33.